Pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of plant origin; anti-cancer preparations of chemical origin; compounds for treating cancer; tumor suppressing ag Read More

Classification Information

Class [005]
Pharmaceutical Products

Class [042]
Computer & Software Services & Scientific Services

Development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; research and development of pharmaceuticals in the fields of oncology, immunology and immuno-oncology; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development in the field of cancer therapeutics, oncology, nanoparticles, and targeted therapies; research and development in the field of recombinant proteins and antibodies for therapeutic and prophylactic use; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new therapeutic proteins and antibodies; development of pharmaceuticals, pharmaceutical ingredients, and antibodies; scientific study and research in the field of developing personal scientific treatment strategies for patients with diagnosed cancer; pharmaceutical services, namely, developing tumor targeting platform technologies; scientific research in the nature of scientific collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the fields of oncology, immunology and immuno-oncology; pharmaceutical product development and evaluation services; pharmaceutical research and development; technical research in the field of pharmaceutical studies; conducting early evaluations in the field of new pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; consulting services in the fields of biotechnology and pharmaceutical research; consulting services for others in the field of design, planning, and implementation of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Class [044]
Medical, Beauty & Agricultural Services

Medical screening; medical monitoring, testing, inspection and analysis services; medical services relating to the diagnosis and treatment of cancerous diseases; pharmaceutical advisory services; medical laboratory analysis services relating to the treatment of persons; medical laboratory analysis services relating to the diagnosis and treatment of cancerous diseases; providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; RNA or DNA analysis for cancer diagnosis and prognosis; medical services in the field of oncology, immunology and immuno-oncology; providing advice relating to oncology, immunology and immuno-oncology; providing on-line information relating to oncology, immunology and immuno-oncology

Class [045]
Personal & Legal & Social Services

Licensing of intellectual property rights; licensing of industrial property rights

Mark Details

Serial Number

No 90424617

Mark Type

No Service Mark

Attorney Docket Number

No 331566-20000

44D Filed

44D Current

44E filed

44E Current

66A Filed

66A Current

Current Basis

No Basis

Legal History

Status Date	Action Taken
07^th Jun 2022	NOTICE OF REGISTRATION CONFIRMATION EMAILED
07^th Jun 2022	REGISTERED-PRINCIPAL REGISTER
29^th Apr 2022	ELECTRONIC RECORD REVIEW COMPLETE
01^st Apr 2022	ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
15^th Feb 2022	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
15^th Feb 2022	PUBLISHED FOR OPPOSITION
26^th Jan 2022	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10^th Jan 2022	LAW OFFICE PUBLICATION REVIEW COMPLETED
10^th Jan 2022	APPROVED FOR PUB - PRINCIPAL REGISTER
10^th Jan 2022	EXAMINER'S AMENDMENT ENTERED

IGEG